Cathay Pacific released its 2025 annual performance, with a profit attributable to shareholders of HKD 10.828 billion, representing a year-on-year increase of 9.51%. China Metallurgical Group reported new contract signings amounting to RMB 132.44 billion in the first two months, marking a year-on-year decrease of 6.49%.
Material Matters:
Guanghe Technology (01989) is conducting an initial public offering from March 12 to March 17, with a planned global issuance of 46 million H-shares.
Sino Biopharm (01177): Clinical trial for TQB3205 (pan-KRAS inhibitor) approved by NMPA.
Binhai Investment (02886) entered into a strategic cooperation framework agreement with Teda Urban Renewal to jointly promote the construction of 'quality housing' under the national initiative and enhance urban quality.
Hengrui Pharma (01276): SHR-2524 injection received clinical trial approval notification.
Lepu Biotechnology-B (02157): AstraZeneca has paid a milestone payment of 45 million US dollars.
Operating Performance:
Laopu Gold (06181) announced a profit alert, expecting its net profit for the fiscal year 2025 to be approximately RMB 4.8 billion to RMB 4.9 billion, representing a year-on-year increase of about 226% to 233%.
Cathay Pacific (00293) announced its financial results for the fiscal year 2025, with a profit attributable to shareholders of HKD 10.828 billion, representing a year-on-year increase of 9.51%.
China Metallurgical Group (01618): New contract value signed in the first two months amounted to 132.44 billion yuan, representing a year-on-year decrease of 6.49%.
Far East Horizon (03360) announced its 2025 financial results, with profit attributable to shareholders amounting to 3.889 billion yuan, marking a year-on-year increase of 0.67%.
Yue Yuen Industrial (Holdings) Ltd. (00551) announced its 2025 financial results, with profit attributable to owners of the company amounting to approximately USD 381 million, representing a year-on-year decrease of 2.9%.
